Renaissance IPO ETF

IPO

Valor de mercado US$ 137 mi

IP Group PLC (LSE:IPO) has invested £4 million in a £36 million funding round for portfolio company Microbiotica, backing the development of a potential new treatment for ulcerative colitis. The Series C financing, led by British Business Bank, will support the progression of Microbiotica's lead drug candidate, MB310, into Phase 2 clinical trials following encouraging early-stage results.

Anthropic is heading toward a potential blockbuster IPO, fueled by rapid revenue growth, major AI deals and ambitious valuation targets.

Kristin Peterson, Barclays Technology Investment Banking global head, joins 'Squawk on the Street' to discuss the retail appetite for tech IPOs.

The 2026 IPO window blew open this summer. SpaceX's June listing pulled in a reported $86 billion according to Benzinga and other outlets, and Anthropic is now being floated as the next challenger to that record, with OpenAI chatter never far behind.

The next phase of the IPO rally could extend beyond tech mega-deals, driven by a more diversified pipeline, benefiting ETFs like FPX and IPO.

Anthropic's potential IPO could be a blockbuster. Here's how AI and IPO-focused ETFs may benefit from one of the biggest listings in tech.

SpaceX could be the catalyst for a surge as the U.S. IPO market eyes a comeback. ETFs like FPX, IPO and IPOS offer an easy way to gain exposure.

Three IPOs priced this past week, joined by two SPACs, and one major issuer joined the pipeline. One IPO and one direct listing are currently scheduled in the week ahead, although some smaller issuers may join the calendar throughout the week. Street research is expected for one company in the week ahead, and three lock-up periods will be expiring.

The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store openings. Abivax reported strong clinical trial results for its obefazimod treatment to address ulcerative colitis in a longer lasting manner.

This year was supposed to be a blockbuster for tech offerings of all sizes.